Novartis Abandons Heart Drug After Surprising Failure in Key Study

Novartis is largely abandoning an experimental drug that analysts had viewed as a potential blockbuster after a study found little promise for preventing heart attacks and cardiovascular deaths. The report signals a negative setback for the drug’s prospects, but provides no financial figures or share-price reaction.